Table 2.

Clinical, echocardiographic, and biomarker characteristics of 43 patients before and after treatment with anthracyclines and trastuzumab

Variable	Baseline	3 Months	6 Months	p Value (ANOVA)
Systolic blood pressure (mm Hg)	122 ± 17	116 ± 18	119 ± 15	0.07
Diastolic blood pressure (mm Hg)	74 ± 9	72 ± 10	72 ± 9	0.33
Heart rate (beats/min)	69 ± 10	72 ± 10	73 ± 11	0.10
LV end-diastolic volume (ml)	74 ± 13	74 ± 18	76 ± 8	0.58
LV end-systolic volume (ml)	26 ± 7	28 ± 9	33 ± 11	<0.0001
LVEF	0.65 ± 0.06	0.63 ± 0.06	0.59 ± 0.05	<0.0001
LV end-diastolic diameter (mm)	43 ± 4	43 ± 3	44 ± 4	0.16
Relative wall thickness	0.39 ± 0.07	0.37 ±0.06	0.37 ± 0.06	0.12
Longitudinal strain (%)	20.5 ± 2.2	19.3 ± 2.4*	18.4 ± 3	<0.0001
Radial strain (%)	55 ± 12	52 ± 12	46 ± 14	0.02
Circumferential strain (%)	18 ± 4	15 ± 4‡	14 ± 3	0.001
Left atrial volume (ml)	32 ± 12	32 ± 9.5	32 ± 11.5	0.91
Mitral E-wave filling velocity (cm/s)	77 ± 17	75 ± 19	76 ± 18	0.36
Mitral A-wave filling velocity (cm/s)	67 ± 15	65 ± 15	64 ± 19	0.69
Mitral E-wave filling velocity/mitral A-wave filling velocity	1.2 ± 0.3	1.2 ± 0.3	1.3 ± 0.4	0.44
Peak early diastolic mitral annular velocity (cm/s)	12.5 ± 2.8	11.8 ± 3.1†	11 ± 2.5	0.004
Peak late diastolic mitral annular velocity (cm/s)	10 ± 3	10 ± 3	9 ± 2	0.11
Mitral E-wave filling velocity/peak early diastolic mitral annular velocity	6.7 ± 2	6.8 ± 2.6	7 ± 2.3	0.59
hsTnI (µg/L)	0.00 ± 0.01	0.04 ± 0.13	0.02 ± 0.07	0.09
NT-proBNP (pg/ml)	103 ± 73	98 ± 105	91 ± 114	0.12

Data are expressed as mean ± SD.

^*p <0.001.

^†p <0.02.

^‡p = 0.001 versus baseline.

ANOVA = analysis of variance; LV = left ventricular.